• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

NEOPHARM to Host Analyst/Investor Corporate Update and Pipeline Review on September 20, 2006

Posted on: Wednesday, 13 September 2006, 09:01 CDT

NEOPHARM, Inc. (Nasdaq:NEOL) today announced that it will host its first corporate update and pipeline review for analysts and investors on Wednesday, September 20, 2006, from 10:00 a.m.-1:00 p.m. Eastern Time. To access the live audio broadcast or the subsequent archived recording log on to http://www.neopharm.com, and click on "Investors" from the main menu.

NEOPHARM's management and external clinicians will review the Company's current strategy for the clinical development of its novel cancer therapies, including CINTREDEKIN BESUDOTOX for first recurrent glioblastoma multiforme.

Company Presenters

-- Guillermo Herrera, President and Chief Executive Officer;

-- Jeffrey Sherman, MD, FACP, Chief Medical Officer and Executive Vice President; and

-- Tim Walbert, Executive Vice President, Commercial Operations.

Invited Academic Clinical Experts

-- Sandeep Kunwar, M.D., Associate Professor of Neurological Surgery, University of California, San Francisco (UCSF), and PI of the CINTREDEKIN BESUDOTOX (IL13-PE38QQR) PRECISE trial will discuss CINTREDEKIN BESUDOTOX development and status of the Phase 3 PRECISE trial.

-- John Sampson, M.D., Associate Professor of Neurosurgery and Assistant Professor of Pathology, Duke University Medical Center, and PRECISE trial investigator will give an overview of the catheter placement procedure.

-- Michael Vogelbaum, M.D., Ph.D., Vice-Chairman and Associate Director of Neurosurgical Oncology, Brain Tumor Institute, Cleveland Clinic Foundation, and PRECISE trial investigator will discuss the clinical issues and current treatments for glioblastoma multiforme.

A presentation on catheter placement, including a demonstration of BrainLAB planning software to optimize catheter positioning, will be given by John Sampson, M.D., and BrainLAB. BrainLAB supplies study support services to the Company in connection with PRECISE.

NEOPHARM's Commitment to Oncology

NEOPHARM employees share a common goal: bringing hope to cancer patients and their families through the research and development of new cancer drugs and therapies. The Company's oncology portfolio is built on two novel, proprietary platforms: a tumor-targeting platform, and the NeoLipid(R) Liposomal Drug Delivery platform. Through its research and clinical studies, as well as its work with physicians, scientists, and advocacy groups, NEOPHARM is helping to enhance the lives of cancer patients.

About NEOPHARM, Inc.

NEOPHARM, Inc., based in Waukegan, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. Additional information, including ongoing clinical trials, can be obtained by visiting NEOPHARM's Web site at www.neopharm.com.

Forward Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects,""intends,""hopes,""anticipates,""believes,""could,""may,""evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in financing, development, testing, obtaining regulatory approval, production and marketing of the Company's drug and non-drug compounds, including, but not limited to, cintredekin besudotox, uncertainty regarding the Company's ability to market its drug and non-drug products including, but not limited to, cintredekin besudotox, and other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission including its annual reports on Form 10-K and quarterly reports on Forms 10-Q. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on these forward-looking statements as a prediction of actual future results.

Source: Business Wire

More News in this Category